Bayer Protests 'Incomprehensible' German Decision on Stivarga In mCRC

A decision by the German health technology assessment agency IQWiG that new analysis provided by Bayer of Stivarga (regorafenib) in metastatic colorectal cancer (mCRC) result in the product's disadvantages outweighing its benefits "is essentially incomprehensible to Bayer," the German pharma told Scrip.